

50

JCWSCS 18 FEB 2004

02/17/2004 TUE 16:00 FAX 510 262 7095 Berlex Biosciences

001/005

Berlex Biosciences
Corporate Patents
2600 Hilltop Drive
Richmond, California 94806
(510) 669-4529
(510) 262-7095 FAX



Fax

To: Mail Stop Office of Initial Patent

From: Wendy L. Washtien

Examination's Filing Receipt Corrections

Fax: 703-746-9195

Pages: 5 (includes cover page)

Phone:

Date: February 17, 2004

Re: Filing Receipt Correction

CC:

☐ **Urgent**

☐ **For Review**

☐ **Please Comment**

☐ **Please Reply**

☐ **Please Recycle**

Case: 52339AUSM1

In re Application of: DOLE et al.

Serial No. 10/642,255

Filing Date: August 15, 2004

Items Faxed: Transmittal (2pgs)
Copy of Filing Receipt

52339AUSM1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
Dole et al. :
Serial No.: 10/642,255 : Group Art Unit: 1614
Filed: August 15, 2003 : Examiner: Not yet known
For: Gene Therapy for Critical Limb Ischemia with Wild-Type or Mutant eNOS
Mail Stop Office of Initial Patent Examination's
Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
via Facsimile: 703-746-9195

FILING RECEIPT CORRECTION

Sir:

Applicants hereby request a review of the Filing Fee indicated on the Filing Receipt we received, Confirmation No. 3168 mailed on January 22, 2004 for the above - referenced application.

The amount of the Filing Fee indicated on the Filing Receipt is \$2,158.00. However, we calculated a total filing fee of \$1,492.00 which comprised the following:


Basic Filing Fee	=	\$750.00
21 extra claims	=	\$378.00
1 extra independent claim	=	\$84.00
Multiple Dependent claim	=	<u>\$280.00</u>
Total	=	\$1,492.00

In addition, the amount withdrawn from our Deposit Account was \$2,050.00 broken down as follows:

	\$750.00
	84.00
	936.00
	<u>280.00</u>
Total	\$2,050.00

Please review the calculation of the Filing Fees owed in this application and if you concur that there is an overcharge, please credit our Deposit Account 02-2117.

Respectfully submitted,



Wendy L. Washtien, Ph.D.
Agent for Applicants
Reg. No. 36301

Berlex Biosciences
2600 Hilltop Drive
Richmond, CA 94806
Telephone: (510) 262-5411
Fax: (510) 262-7095
Date: February 17, 2004

Title

Gene therapy for critical limb ischemia with wild type or mutant eNOS

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).